Mimi Lee

Dr. Mimi Lee is a visionary leader, thinker and healer. She draws from disparate expertise and experiences across academic and community medical practice, as a cancer survivor, and as a global team member in industrial innovative genetic medicines developer. She leads with systems level perspectives, taking time to understand and drive multistakeholder interests and needs to ultimately make real impact for real patients in the real world in real time. 

Mimi currently serves as Chief of Precision Genetic Medicine at GeneDx, where she is building an innovation hub to disrupt the standard of medical care for all people living with conditions that can be characterized at the genomic level. She envisions an end-to-end solution that integrates sequencing and therapeutic design and development into one seamless process. Mimi is committed to those populations with the highest unmet needs, the rare disease community, who she believes will catalyze the medical paradigm empowered by genomics and genetic bioengineering for all.

Before joining GeneDx, Mimi served at the Advanced Research Projects Agency for Health (ARPA-H), where she designed and directed high-impact public–private programs to advance individualized genetic medicines, including the landmark THRIVE initiative (Treating Hereditary Rare Diseases with In Vivo Precision Genetic Medicines) aimed to drive systemic ecosystem change through technology advances. She brings more than two decades of experience spanning academia, biotechnology, and global industry, with previous leadership roles at Samsung Bioepis, Novartis Institutes for Biomedical Research, and BioMarin. 

At DoriNano, Mimi brings a uniquely integrative perspective across science, medicine, ethics, and systems-level strategy. She will help guide clinical translation, patient stratification strategy, and regulatory framing for genetic and immunological applications of our DNA-origami platform. Mimi’s experience convening multidisciplinary stakeholders will also strengthen DoriNano’s partnership ecosystem, inform real-world evidence planning, and support our mission to deliver truly transformative therapies to the patients who need them most.

Mimi earned her MD–PhD in Neuroscience from the Albert Einstein College of Medicine as part of the NIH Medical Scientist Training Program. She holds an AB in Chemistry and East Asian Languages and Civilizations from Harvard University, completed her residency training at Washington University School of Medicine in St. Louis and the University of California, San Francisco, and holds additional certifications in Bioethics from Columbia University and Psychedelic-Assisted Therapy from the California Institute of Integral Studies.